The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
The disclosure relates to compositions comprising a nucleotide sequence having two domains: a locked nucleic acid domain and a DNA gap domain, wherein nucleotide sequence binds to an endogenous DUX4 mRNA sequence disrupts DUX4 expression.
The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.
The present disclosure relates to 2-(3 -indolyl)indolin-3 -one derivatives of the natural product isatisine A, synthesized from dual catalytic synthesis on metalocarbene-azide cascade chemistry, useful for treating a subject having or suspected of having an infectious disease, wherein said...
A device for replacing a mitral valve includes a substantially cylindrically-shaped body having a top portion, a bottom portion, and a waist portion disposed therebetween and having ferromagnetic elements arranged circumferentially, and the top portion, waist...
Generating a plan for radiation treatment of multiple target volumes such as, for example, multiple brain tumors, involves optimizing a grouping of the target volumes into subsets and generating treatment plans for each subset. Resulting treatment...
The present invention provides a method for removing a tattoo in a region of skin the method comprises administering to a least a portion of the tattoo a composition comprising an effective amount of a bisphosphonate and at least one pharmaceutically acceptable...
The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular...
The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide...
The present disclosure is directed recombinant T cell receptors capable of binding an gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide...
A spatial parallel mechanism comprises a platform. Three or more legs configured for extending from a base or ground to the platform, each leg has a distal link, one or more distal joint providing one rotational degree of freedom (DOF) about a distal rotational...
The present disclosure relates to compounds of the Formula (I) which have shown utility in modulating AMPA receptor signaling and thus preventing AMPA receptor-mediated toxicity, which may find use in the treatment of diseases in which AMPA receptor activation plays a role in...
Provided are humanized anti-HLA-A2 antibodies. In certain aspects, the humanized anti-HLA-A2 antibodies are capable of constituting an antigen binding domain of a chimeric antigen receptor (CAR), where the CAR is capable of being expressed in a human cell such that the...
and their potential utility in catalyzing α-alkylation of secondary amine-containing moieties.
A method for preparing a kefir product involves providing bacterial strains selected from Acetobacter, Leuconostoc, Lactococcus, or Lactobacillus; providing yeast strains selected from Pichia, Saccharomyces, Kazachstania, or Kluyveromyces; adding the bacterial and yeast...
The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence...
PROBLEM TO BE SOLVED: To provide a method for treating a hematological cancer, preferably a leukemia selected from acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia,...
The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence...
The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide...
A lipid nanoparticle composition is disclosed. The lipid nanoparticle composition includes: a core, and a lipid mixture encapsulating the core. The core includes: (i) a complex of a poly-(beta-amino ester) polymer with DNA or RNA; or (ii) a peptide. The lipid mixture encapsulating the core includes:...
